Mindaugas Jurgutis

711 total citations · 1 hit paper
7 papers, 447 citations indexed

About

Mindaugas Jurgutis is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Mindaugas Jurgutis has authored 7 papers receiving a total of 447 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 6 papers in Hematology and 2 papers in Molecular Biology. Recurrent topics in Mindaugas Jurgutis's work include Chronic Myeloid Leukemia Treatments (6 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Mindaugas Jurgutis is often cited by papers focused on Chronic Myeloid Leukemia Treatments (6 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Mindaugas Jurgutis collaborates with scholars based in United Kingdom, France and Hungary. Mindaugas Jurgutis's co-authors include Mark W. Drummond, Alessandro M. Vannucchi, Elena Mishchenko, Claire Harrison, Éric Jourdan, Tamás Masszi, Animesh Pardanani, Ayalew Tefferi, Kazimierz Kuliczkowski and Emanuil Gheorghita and has published in prestigious journals such as Blood, British Journal of Haematology and BMC Cancer.

In The Last Decade

Mindaugas Jurgutis

7 papers receiving 443 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis

2015 340 citations Animesh Pardanani, Claire Harrison et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mindaugas Jurgutis United Kingdom	5	373	281	203	137	62	7	447
Elena Mishchenko Israel	6	384 1.0×	291 1.0×	220 1.1×	159 1.2×	58 0.9×	12	461
Emanuil Gheorghita Romania	4	316 0.8×	249 0.9×	182 0.9×	122 0.9×	54 0.9×	4	387
Clara Ricci Italy	7	163 0.4×	227 0.8×	173 0.9×	53 0.4×	40 0.6×	9	367
D. W. Kim United States	8	411 1.1×	507 1.8×	67 0.3×	261 1.9×	124 2.0×	9	592
Hyacinthe Johnson‐Ansah France	9	293 0.8×	353 1.3×	31 0.2×	161 1.2×	90 1.5×	18	414
Cristina Bucelli Italy	9	162 0.4×	173 0.6×	81 0.4×	73 0.5×	34 0.5×	33	250
Amity Frede Australia	8	323 0.9×	396 1.4×	58 0.3×	174 1.3×	123 2.0×	13	472
Fabian Lang Germany	8	164 0.4×	227 0.8×	67 0.3×	69 0.5×	53 0.9×	39	285
Katy Knight United Kingdom	7	120 0.3×	179 0.6×	35 0.2×	85 0.6×	78 1.3×	8	253
Nataliia Glushko Singapore	2	217 0.6×	275 1.0×	42 0.2×	120 0.9×	77 1.2×	2	327

Countries citing papers authored by Mindaugas Jurgutis

Since Specialization

Citations

This map shows the geographic impact of Mindaugas Jurgutis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mindaugas Jurgutis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mindaugas Jurgutis more than expected).

Fields of papers citing papers by Mindaugas Jurgutis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mindaugas Jurgutis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mindaugas Jurgutis. The network helps show where Mindaugas Jurgutis may publish in the future.

Co-authorship network of co-authors of Mindaugas Jurgutis

This figure shows the co-authorship network connecting the top 25 collaborators of Mindaugas Jurgutis. A scholar is included among the top collaborators of Mindaugas Jurgutis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mindaugas Jurgutis. Mindaugas Jurgutis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Pardanani, Animesh, Ayalew Tefferi, Tamás Masszi, et al.. (2021). Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis. British Journal of Haematology. 195(2). 244–248. 40 indexed citations

2.

Pardanani, Animesh, Ayalew Tefferi, Tamás Masszi, et al.. (2020). Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial. Blood. 136(Supplement 1). 10–12. 2 indexed citations

3.

Beinortas, Tumas, et al.. (2016). Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000–2013. BMC Cancer. 16(1). 198–198. 14 indexed citations

4.

Pardanani, Animesh, Claire Harrison, Jörge E. Cortes, et al.. (2015). Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis. JAMA Oncology. 1(5). 643–643. 340 indexed citations breakdown →

5.

Mesa, Ruben A., Jörge E. Cortes, Francisco Cervantes, et al.. (2013). Symptom Burden and Health-Related Quality Of Life (HRQoL) In Patients With Myelofibrosis (MF) Treated With Fedratinib (SAR302503) In a Phase III Study (JAKARTA). Blood. 122(21). 4061–4061. 3 indexed citations

6.

Pardanani, Animesh, Claire Harrison, Jörge E. Cortes, et al.. (2013). Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF). Blood. 122(21). 393–393. 27 indexed citations

7.

Jurgutis, Mindaugas, et al.. (2011). Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia. Leukemia & lymphoma. 52(6). 1055–1065. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact